[Australia] A unique seaweed extract showed promise for the treatment of Helicobacter pylori (H. pylori)-related diseases and gastric cancer, according to new research undertaken at the University of Western Australia. Published in Evidence-based Complementary and Alternative Medicine, the research involved testing fucoidan extracts derived from the Fucus vesiculosus and Undaria pinnatifida species of brown seaweed. The certified organic, high-purity extracts were developed and produced by Australian biotechnology company, Marinova Pty Ltd.
The in vitro studies showed fucoidan extracts are extremely effective at dislodging H. pylori from infected human stomach cancer cells. This significant result positions fucoidan as a potential alternative to antibiotic treatments.
The study also showed fucoidan exhibited significant anti-cancer activity. Researchers found the fucoidan extracts were profoundly toxic to human gastric cancer cells in vitro.
Future human clinical trials will further investigate the potential for these seaweed extracts to treat gastric cancer and other H. pylori-related diseases.
View original article at: Seaweed extract and Helicobacter pylori treatment